ArticleOral oncology2011

Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.

Shousong Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.